Navigation Links
As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing
Date:8/22/2012

Rockville, MD, & Seattle, WA, USA (August 22, 2012) Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.

Tuberculosis (TB), which kills more people than any other infectious disease except HIV, has orphaned 10 million children, and costs the global economy an estimated $1 billion every day. An increasing number of diagnosed multidrug-resistant TB cases are making the disease more difficult to control and multiplying the cost and time it takes to treat patients, which can take two years or longer for multidrug-resistant TB.

The vaccine candidate targets both active tuberculosis, which makes nearly 9 million people sick each year, and latent TB, which lies dormant in one-third of the world's population and reactivates when their immune systems are compromised.

"An effective TB vaccine for adolescents and adults would be the single most cost-effective intervention against tuberculosis," said Tom Evans, Aeras Chief Scientific Officer. "With cases of drug-resistant TB on the rise, it is urgent to deliver an effective TB vaccine regimen to those who need it as soon as possible."

The vaccine candidate, ID93 + GLA-SE, is composed of a recombinant fusion-protein antigen designed by IDRI to recognize both active and latent TB, plus IDRI's proprietary adjuvant, GLA-SE, which has been previously tested in humans. In pre-clinical studies, the vaccine candidate had an acceptable safety profile in animals and demonstrated substantial protection against Mycobacterium tuberculosis the bacterium that causes TB.

"With NIH support enabling our TB program, IDRI has designed and tested the safety and efficacy of this vaccine candidate in several pre-clinical models," said Steven Reed, Ph.D., IDRI president, founder and Chief Scientific Officer. "The start of the first clinical trial is a significant milestone following nearly seven years of work on this vaccine candidate, which is designed to produce a robust immune response to prevent, and possibly to treat, TB."

The currently available TB vaccine, Bacille Calmette-Gurin (BCG), developed 90 years ago, reduces the risk of severe forms of TB in early childhood but has been ineffective in controlling the global TB epidemic despite widespread use. Aeras and IDRI, two non-profit product development partnerships, are committed to making new TB vaccines available to those who need them most in TB endemic countries.


'/>"/>
Contact: Jamie Rosen
jrosen@aeras.org
301-547-2853
Aeras
Source:Eurekalert

Related biology news :

1. New York Stem Cell Foundation scientist grows bone from human embryonic stem cells
2. A new line of defense: Researchers find cattle vaccine works to reduce E. coli O157:H7
3. Duke selected to receive multi-million dollar grant for HIV vaccine
4. Scripps Research Institute wins $77 million to develop AIDS vaccine center
5. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
6. Overweight? Theres a vaccine for that
7. Sensitive test helps improve vaccine safety
8. Army study: DNA vaccine and duck eggs protect against hantavirus disease
9. AAPS National Biotechnology Conference to highlight innovative vaccines
10. Researchers identify Achilles heel of dengue virus, target for future vaccines
11. SFU HIV/AIDS vaccine research gets financial boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series ... 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population ... challenge of how to continue to feed a growing nation. At the same time, ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
Breaking Biology Technology: